DNA immunotherapy for recurrent respiratory papillomatosis (RRP): phase 1/2 study assessing efficacy, safety, and immunogenicity of INO-3107

M Matthew P. Morrow E Elisabeth Gillespie A Albert Sylvester M Milan R. Amin P Peter C. Belafsky S Simon R. Best A Aaron D. Friedman A Adam M. Klein D David G. Lott T Ted Mau R Randal C. Paniello S Seth M. Pransky N Nabil F. Saba G Grace S. Tan S Sadie Wisotsky S Sarah A. Marcus E Emma L. Reuschel K Katherine S. Reed D David B. Weiner (Vaccine and Immunotherapy Center, The Wistar Institute) M Michael Dallas J Jeffrey M. Skolnik

Article Details

Volume / Issue Vol. 16, Issue 1
Published February 12, 2025
ISSN 2041-1723
Publisher Nature Portfolio

Journal Info

Nature Communications

Nature Portfolio

ISSN: 2041-1723 Open Access Life Sciences

Authors (21)

M

Matthew P. Morrow

E

Elisabeth Gillespie

A

Albert Sylvester

M

Milan R. Amin

P

Peter C. Belafsky

S

Simon R. Best

A

Aaron D. Friedman

A

Adam M. Klein

D

David G. Lott

T

Ted Mau

R

Randal C. Paniello

S

Seth M. Pransky

N

Nabil F. Saba

G

Grace S. Tan

S

Sadie Wisotsky

S

Sarah A. Marcus

E

Emma L. Reuschel

K

Katherine S. Reed

D

David B. Weiner

Vaccine and Immunotherapy Center, The Wistar Institute

M

Michael Dallas

J

Jeffrey M. Skolnik